UNITY Biotechnology Inc At KOL Webinar Call Transcript
Good morning, and welcome to the Unity Biotechnology KOL webinar and update to the lead program, UBX1325. (Operator Instructions) As a reminder, this call is being recorded, and a replay will be made available on the Unity Biotechnology website following the conclusion of the event. I'd now like to turn the call over to Lynne Sullivan, CFO and Head of Corporate Development at Unity Biotechnology. Please go ahead, Lynne.
Good morning. Thank you for joining Unity Biotechnology's conference call this morning to discuss the 24-week data results from our Phase I single ascending dose study of UBX1325. We will also be sharing 12-week data from an additional cohort of 7 AMD patients dosed at 10 micrograms.
With us on today's call is Dr. Robert Bhisitkul, Professor of Ophthalmology and Director of the Retina Fellowship at the University of California San Francisco; and Dr. Arshad Khanani, Managing Partner and Director of Clinical Research at Sierra Eye
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |